|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Walgreens (WBA) along with privately-held global investment firm KKR completes the acquisition of Pharmerica for $1.4 billion. The merger agreement was announced in August.
The all-cash acquisition of PharMerica Corp. by a joint venture of KKR & Co. L.P. and Walgreens Boots Alliance Inc. was completed last week. As part of the merger agreement, all stock options and awards for PharMerica executives and directors have become fully vested and converted into the right to cash in as well. After the completion of the acquisition was announced on Dec. 7, 12 of the company's top executives and directors sold their stock and filed disclosures with the U.S. Securities and Exchange Commission the next day.
CEO of Pharmerica Corp (NYSE:PMC) Gregory S Weishar sold 521,089 shares of PMC on 12/07/2017 at an average price of $29.25 a share.
A joint venture between KKR & Co. L.P. and Walgreens Boots Alliance Inc. has completed its acquisition of Louisville-based institutional pharmacy provider PharMerica Corp. in a $1.4 billion deal. PharMerica (PMC) shareholders will receive $29.25 per share for their stock in the company, which will cease trading on the New York Stock Exchange tomorrow. PharMerica announced the merger in August and said the deal would be completed in early 2018.
PharMerica Corporation today announced the completion of the acquisition of PharMerica by a newly formed company controlled by KKR with an affiliate of Walgreens Boots Alliance, Inc.
PharMerica Corporation (NYSE:PMC) delivered a less impressive 4.28% ROE over the past year, compared to the 14.78% return generated by its industry. Though PMC’s recent performance is underwhelming, it isRead More...
On a per-share basis, the Louisville, Kentucky-based company said it had profit of 10 cents. Earnings, adjusted for amortization costs and costs related to mergers and acquisitions, were 46 cents per share. ...
PharMerica Corporation , a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today reported its financial results for the third quarter ended September 30, 2017.
Shareholders of Louisville-based PharMerica Corp. voted overwhelmingly to approve the company's $1.4 billion acquisition by KKR & Co. L.P. and Walgreens Boots Alliance. More than 99 percent of the votes cast, representing about 79 percent of PharMerica's common shares as of Sept. 28 (the record date for the special meeting), were in favor of adopting the merger agreement, according to a news release. The deal calls for PharMerica to be acquired by a new company controlled by KKR, a New York City-based private-equity firm, with Deerfield, Ill.-based Walgreens Boots Alliance Inc. (WBA) as a minority investor.
PharMerica Corporation , announced that at its special meeting of stockholders held today, a majority of the outstanding shares of PharMerica common stock voted to approve the adoption of the previously disclosed definitive merger agreement pursuant to which a newly formed company controlled by KKR, with Walgreens Boots Alliance, Inc.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for PharMerica Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives PharMerica Corp. a score of 47. Our analysis is based on comparing PharMerica Corp. with the following peers – Walgreens Boots Alliance Inc, CVS Health Corporation, BioScrip, Inc., Rite Aid Corporation, Kindred Healthcare, Inc., AmerisourceBergen Corporation, SunLink Health Systems, Inc. and Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for PharMerica Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Onco360, the nation’s largest independent Oncology Pharmacy, announced today that it has been selected to participate in the limited distribution network for Eli Lilly and Company’s new product, VERZENIOTM , a twice daily oral cyclin-dependent kinase 4/6 inhibitor approved by the U.S.
PharMerica Corp. executives could receive millions from the company if they are terminated after the completion of its planned $1.4 billion acquisition. The so-called "golden parachute compensation" for the company's named executives could total about $27.7 million, according to a filing with the U.S. Securities and Exchange Commission. PharMerica has agreed to be acquired by a new company, Phoenix Parent Holdings Inc., which is controlled by New York-based KKR & Co. L.P., with Deerfield, Ill.-based Walgreens Boots Alliance Inc. (WBA) as a minority investor.
NEW YORK, Oct. 3, 2017 /PRNewswire/ -- Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the District of Delaware, case No. 1:17-cv-01301, on behalf of shareholders of PharMerica Corporation ("PharMerica" or the "Company") (PMC) who have been harmed by PharMerica's and its board of directors' (the "Board") alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the proposed merger of the Company with affiliates of Kohlberg Kravis Roberts & Co. L.P. ("KKR").
Categories: Yahoo FinanceGet free summary analysis PharMerica Corp. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 592 million, Net Earnings of USD 4.70 million. Gross margins narrowed from 14.16% to 13.46% compared to the same period last year, operating (EBITDA) margins now 5.84% from 6.12%. Change in operating cash ... Read more (Read more...)
Rating Action: Moody's assigns B2 CFR to PharMerica Corporation; outlook stable. Global Credit Research- 12 Sep 2017. New York, September 12, 2017-- Moody's Investors Service today assigned a B2 Corporate ...
NEW YORK , Sept. 7, 2017 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...
The healthcare team led by James Momtazee has been very busy, with deals for PharMerica, American Medical Response and Covenant Surgical Partners, among others.
Envision Healthcare's (EVHC) increasing debt and expenses continue to hurt. Further guidance cut by the company is concerning.
LONDON, UK / ACCESSWIRE / August 4, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for PharMerica Corp. (NYSE: PMC ), following which we have published ...
Categories: Yahoo FinancePharMerica Corp. relative valuation is OVERVALUED and it has a fundamental analysis score of 47. Our analysis is based on comparing PharMerica Corp. with the following peers – Walgreens Boots Alliance Inc, CVS Health Corporation, BioScrip, Inc., Rite Aid Corporation, Kindred Healthcare, Inc., SunLink Health Systems, Inc., AmerisourceBergen Corporation and Guangzhou Baiyunshan Pharmaceutical Holdings Company ... Read more (Read more...)
Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of PharMerica Corporation stockholders concerning the proposed acquisition of the company by KKR & Co.